---
title: "VK2735 in Chronic weight management: Limitations of current therapies"
description: "Formulary evidence on VK2735 in Chronic weight management: Limitations of current therapies. Topics: Summary: limitations of current therapies, Weight regain after withdrawal of semaglutide 2.4 mg in the STEP 1 extension, Weight regain after withdrawal of tirzepatide in SURMOUNT-4, Rate of weight regain after cessation of weight management medications, and 7 further topics. 11 evidence topics quoted from 11 sources."
canonical: "https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-15T21:45:47-05:00"
modified: "2026-11-15T21:45:47-05:00"
---

# VK2735 in Chronic weight management: Limitations of current therapies

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

### Summary: limitations of current therapies

In the STEP 1 extension, participants who stopped semaglutide 2.4 mg at week 68 regained 11.6 of 17.3 percentage points of lost weight by week 120. In SURMOUNT-4 (670 randomized participants), those switched from tirzepatide to placebo regained 14% of body weight over 52 weeks, while those who continued tirzepatide lost a further 5.5%. A 2026 meta-analysis of 37 studies (9,341 participants) estimated weight regain of 0.4 kg per month after cessation of weight management medication, with cardiometabolic markers projected to return to baseline within 1.4 years. In commercial claims, 1-year persistence among adults without diabetes was 32.3% for initiators in 2021 and 60.9% for initiators of semaglutide (Wegovy) or tirzepatide (Zepbound) in the first half of 2024; the later study states that shortage resolution “may have improved persistence rates”. In a health-system cohort, 1-year discontinuation was 64.8% in adults without type 2 diabetes. ICER states that “there are few data from clinical trials on outcomes beyond 2-3 years” and that there “remain challenges to accessing highly effective obesity medications”. In a 2025 employer survey, 49% of large employers covered GLP-1 medications for weight loss. In the ADA table of older agents, weight loss from baseline was 5% to 9.8% with active treatment and 1.2% to 5.6% with placebo; phentermine is approved only for short-term use; and metabolic surgery carries perioperative mortality of 0.1% to 0.5% with long-term follow-up by the surgical team falling to 30% at two years.

Source: [Wilding et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/); [Aronne et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/); [West et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12776922/); [Gleason et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11293763/); [Marshall et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948759/); [Rodriguez et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11786232/); [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf); [Mercer (2025)](https://www.mercer.com/en-us/about/newsroom/employers-and-workers-face-affordability-crunch-as-health-insurnace-cost-is-expected-to-exceed-18500-per-employee-in-2026/); [American Diabetes Association Professional Practice Committee (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12690172/); [Pennings et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11997402/)

<a id="topic-2.2.2.1.7-2"></a>

### Weight regain after withdrawal of semaglutide 2.4 mg in the STEP 1 extension

> “From week 0 to week 68, mean weight loss was 17.3% (SD: 9.3%) with semaglutide and 2.0% (SD: 6.1%) with placebo. Following treatment withdrawal, semaglutide and placebo participants regained 11.6 (SD: 7.7) and 1.9 (SD: 4.8) percentage points of lost weight, respectively, by week 120, resulting in net losses of 5.6% (SD: 8.9%) and 0.1% (SD: 5.8%), respectively, from week 0 to week 120.”
> “Cardiometabolic improvements seen from week 0 to week 68 with semaglutide reverted towards baseline at week 120 for most variables.”

Source: [Wilding et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/)

<a id="topic-2.2.2.1.7-3"></a>

### Weight regain after withdrawal of tirzepatide in SURMOUNT-4

> “After 36 weeks of open-label maximum tolerated dose of tirzepatide (10 or 15 mg), adults (n = 670) with obesity or overweight (without diabetes) experienced a mean weight reduction of 20.9%. From randomization (at week 36), those switched to placebo experienced a 14% weight regain and those continuing tirzepatide experienced an additional 5.5% weight reduction during the 52-week double-blind period.”

Source: [Aronne et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/)

<a id="topic-2.2.2.1.7-4"></a>

### Rate of weight regain after cessation of weight management medications

> “Of the 9288 titles screened, 37 studies (63 intervention arms, 9341 participants) were included.”
> “The average monthly rate of weight regain was 0.4 kg (95% confidence interval (CI) 0.3 to 0.5) (mixed model 0.3 kg (0.2 to 0.4) monthly v control in RCTs). All cardiometabolic markers were projected to return to baseline within 1.4 years after the cessation of WMM. Weight regain was faster after WMM than after BWMP (by 0.3 kg (0.22 to 0.34) monthly), independent of initial weight loss.”

Source: [West et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12776922/)

<a id="topic-2.2.2.1.7-5"></a>

### Real-world persistence and adherence in commercially insured adults without diabetes

> “Overall, GLP-1 persistence was 46.3% at 180 days and 32.3% at 1 year. The highest and lowest persistence rates at 1 year were observed for semaglutide (Ozempic) at 47.1% and liraglutide (Saxenda) 19.2%, respectively. Average PDC during the 1-year assessment was 51.0% with 27.2% adherent to therapy and 11.1% switched GLP-1 drugs.”

Source: [Gleason et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11293763/)

<a id="topic-2.2.2.1.7-6"></a>

### Persistence trend by year of initiation and drug shortages

> “Across the index years, 1-year persistence increased from 33.2% in 2021 to 60.9% in 1H 2024.”
> “For tirzepatide, 1-year persistence rates in 2023 and 1H 2024 (the only years the product was available) were 64.0% and 64.8%, respectively.”
> “GLP-1RA product shortage resolution may have improved persistence rates.”

Source: [Marshall et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12948759/)

<a id="topic-2.2.2.1.7-7"></a>

### Discontinuation in adults with obesity without type 2 diabetes

> “Patients with obesity only had a higher prevalence of discontinuation at 12 months vs those with T2D only and those with both (50.3% vs 35.8% and 34.2%).”

Source: [Do et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11127113/)

> “One-year discontinuation was significantly higher for patients without type 2 diabetes (64.8% [95% CI, 64.4%-65.2%]) compared with those with type 2 diabetes (46.5% [95% CI, 46.2%-46.9%]).”
> “moderate or severe incident gastrointestinal adverse events were associated with a higher hazard of discontinuation (with type 2 diabetes: HR, 1.38 [95% CI, 1.31-1.45]; without type 2 diabetes: HR, 1.19 [95% CI, 1.12-1.27]).”

Source: [Rodriguez et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11786232/)

<a id="topic-2.2.2.1.7-8"></a>

### Discontinuation for adverse events with injectable incretin therapy

> “A higher proportion of the trial participants receiving semaglutide (8%) discontinued treatment due to adverse events compared to tirzepatide (6%). More participants receiving semaglutide (5.6%) discontinued treatment due to GI-related side effects than those receiving tirzepatide (2.7%).”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.1.7-9"></a>

### Limited long-term outcome and safety data

> “Obesity is a lifelong disease; however, there are a lack of long-term follow-up data for both benefits and harms. For example, there are few data from clinical trials on outcomes beyond 2-3 years, particularly for weight maintenance.”
> “However, we do not yet have data on the impact of discontinuation on other outcomes (e.g., risk of CV events, progression of MASH or CKD, etc.) or data on whether re-treatment in the future conveys the same benefits as initial treatment.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.1.7-10"></a>

### Access to obesity medications and comprehensive care

> “Despite the number of therapies available, there remain challenges to accessing highly effective obesity medications and thus additional options for treatment may be beneficial in closing the treatment gap.”
> “Coupled with the uneven and restricted insurance coverage of obesity medications, very few individuals living with obesity could be considered as having access to comprehensive and affordable obesity care.”

Source: [ICER (2025)](https://icer.org/wp-content/uploads/2025/12/ICER_Obesity_Final-Report_For-Publication_121625-1.pdf)

<a id="topic-2.2.2.1.7-11"></a>

### Employer coverage of GLP-1 medications for weight loss

> “Notably, more large employers covered costly GLP-1 weight-loss medications in 2025 – 49%, up from 44% in 2024.”

Source: [Mercer (2025)](https://www.mercer.com/en-us/about/newsroom/employers-and-workers-face-affordability-crunch-as-health-insurnace-cost-is-expected-to-exceed-18500-per-employee-in-2026/)

## Related pages
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management.md)
- [VK2735 in Chronic weight management: Terms and abbreviations](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/terms-and-abbreviations.md)
- [VK2735: Chronic weight management](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/executive-summary.md)
- [VK2735 in Chronic weight management: Product information and disease description](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/product-information-and-disease-description.md)
- [VK2735 in Chronic weight management: Clinical evidence](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/clinical-evidence.md)
- [VK2735 in Chronic weight management: Economic information and modeling report](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/economics.md)
- [VK2735 in Chronic weight management: References](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references) · [Markdown](https://www.evicenter.com/drugs/vk2735--chronic-weight-management/references.md)
